Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Liver Function

Phase 1 Completed 24 enrolled Fujian Akeylink Biotechnology Co., Ltd.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This si a single-center, non-randomized, open, parallel, single-dose trial was designed to evaluate the safety and pharmacokinetic characteristics of GST-HG171 tablets in subjects with impaired liver function.

Timeline

Start: 2022-12-15
Primary completion: 2023-02-06
Completion: 2023-05-30

Publications

Zhou J, Zhang H, Chen H, Zhang G, Mao J, Zhang T, Tang Y, Yan W, Li C, Ding Y, Jin Q. Pharmacokinetics and safety of GST-HG171, a novel 3CL protease inhibitor, in Chinese subjects with impaired and normal liver function. Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0053924. doi: 10.1128/aac.00539-24. Epub 2024 Jul 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GST-HG171	Small molecule	150 mg	Oral

Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Liver Function

Summary

Timeline

Publications

Drugs

Indications